Profile data is unavailable for this security.
About the company
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. The Company intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.
- Revenue in USD (TTM)0.00
- Net income in USD-95.23m
- Incorporated2005
- Employees65.00
- LocationLarimar Therapeutics IncTHREE BALA PLAZA EAST. SUITE 506BALA CYNWYD 19004United StatesUSA
- Phone+1 (617) 622-4003
- Fax+1 (302) 655-5049
- Websitehttps://larimartx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| enGene Holdings Inc | 0.00 | -79.88m | 187.05m | 56.00 | -- | 0.8224 | -- | -- | -1.65 | -1.65 | 0.00 | 4.45 | 0.00 | -- | -- | 0.00 | -29.57 | -- | -30.97 | -- | -- | -- | -- | -- | -- | -- | 0.094 | -- | -- | -- | 47.35 | -- | -- | -- |
| Omeros Corp | 0.00 | -176.34m | 187.50m | 202.00 | -- | -- | -- | -- | -3.04 | -2.64 | 0.00 | -3.68 | 0.00 | -- | -- | 0.00 | -52.43 | -50.90 | -66.50 | -63.20 | -- | -- | -- | -- | -- | -8.22 | 2.16 | -- | -- | -- | -4.41 | -- | -13.15 | -- |
| Editas Medicine Inc | 35.84m | -251.23m | 190.87m | 246.00 | -- | 3.06 | -- | 5.33 | -3.04 | -3.04 | 0.4338 | 0.7457 | 0.1018 | -- | 94.93 | 145,674.80 | -71.37 | -34.19 | -89.03 | -38.43 | -- | -- | -701.06 | -373.02 | -- | -- | 0.4665 | -- | -58.64 | 9.50 | -54.74 | -- | 7.43 | -- |
| CARGO Therapeutics Inc | 0.00 | -216.19m | 193.22m | 167.00 | -- | 0.6841 | -- | -- | -4.62 | -4.62 | 0.00 | 6.13 | 0.00 | -- | -- | 0.00 | -55.12 | -- | -60.88 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -70.66 | -- | -- | -- |
| Larimar Therapeutics Inc | 0.00 | -95.23m | 194.00m | 65.00 | -- | 1.34 | -- | -- | -1.49 | -1.49 | 0.00 | 2.25 | 0.00 | -- | -- | 0.00 | -45.52 | -45.05 | -49.68 | -50.22 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -118.15 | -- | -7.58 | -- |
| Sellas Life Sciences Group Inc | 0.00 | -27.13m | 194.57m | 15.00 | -- | 6.39 | -- | -- | -0.3911 | -0.3911 | 0.00 | 0.3054 | 0.00 | -- | -- | 0.00 | -91.36 | -125.08 | -142.54 | -231.32 | -- | -- | -- | -1,399.79 | -- | -- | 0.00 | -- | -- | -- | 17.30 | -- | -- | -- |
| Kodiak Sciences Inc | 0.00 | -190.63m | 195.23m | 113.00 | -- | 1.79 | -- | -- | -3.62 | -3.62 | 0.00 | 2.06 | 0.00 | -- | -- | 0.00 | -52.04 | -33.79 | -56.32 | -35.95 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 32.36 | -- | -1.75 | -- |
| ProKidney Corp | 306.00k | -68.43m | 195.73m | 204.00 | -- | -- | -- | 639.64 | -0.6024 | -0.6024 | 0.0027 | -3.41 | 0.0008 | -- | 0.1674 | 1,500.00 | -41.81 | -- | -- | -- | -- | -- | -54,233.33 | -- | -- | -- | 0.0002 | -- | -- | -- | -72.51 | -- | -- | -- |
| Codexis Inc | 49.82m | -74.46m | 198.00m | 188.00 | -- | 3.99 | -- | 3.97 | -0.9885 | -0.9885 | 0.6508 | 0.5991 | 0.3578 | 6.71 | 3.86 | 264,973.40 | -53.48 | -21.95 | -65.18 | -26.20 | 71.56 | 76.67 | -149.47 | -49.88 | 3.64 | -- | 0.3703 | -- | -15.39 | -2.82 | 14.38 | -- | 2.91 | -- |
| TriSalus Life Sciences Inc | 32.14m | -30.30m | 201.30m | 110.00 | -- | -- | -- | 6.26 | -1.05 | -1.05 | 1.19 | -1.06 | 1.38 | 1.31 | 6.61 | 292,190.90 | -116.96 | -- | -267.11 | -- | 85.60 | -- | -84.63 | -- | 1.78 | -8.14 | -- | -- | 58.99 | -- | 47.75 | -- | -- | -- |
| AC Immune SA | 35.42m | -65.19m | 201.82m | 133.00 | -- | 1.70 | -- | 5.70 | -0.6529 | -0.6529 | 0.3535 | 1.18 | 0.1496 | -- | 47.48 | 266,334.30 | -27.53 | -27.41 | -39.31 | -30.60 | -- | -- | -184.05 | -505.58 | -- | -129.20 | 0.0518 | -- | 84.51 | -24.38 | 6.12 | -- | -21.11 | -- |
| Design Therapeutics Inc | 0.00 | -56.20m | 202.66m | 56.00 | -- | 0.8892 | -- | -- | -0.9918 | -0.9918 | 0.00 | 4.01 | 0.00 | -- | -- | 0.00 | -21.77 | -18.88 | -22.44 | -19.44 | -- | -- | -- | -98,925.22 | -- | -- | 0.00 | -- | -- | -- | 25.84 | -- | -- | -- |
| Monopar Therapeutics Inc | 0.00 | -16.57m | 205.47m | 16.00 | -- | 3.83 | -- | -- | -3.46 | -3.46 | 0.00 | 8.76 | 0.00 | -- | -- | 0.00 | -51.78 | -52.66 | -54.27 | -59.31 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -85.50 | -- | -- | -- |
| OmniAB Inc | 26.74m | -61.27m | 207.97m | 114.00 | -- | 0.7591 | -- | 7.78 | -0.5912 | -0.5912 | 0.2582 | 2.24 | 0.0812 | -- | 5.08 | 234,596.50 | -18.60 | -- | -19.46 | -- | -- | -- | -229.11 | -101.09 | -- | -- | 0.00 | -- | -22.75 | 7.58 | -22.55 | -- | 49.04 | -- |
Data as of Jun 30 2025. Currency figures normalised to Larimar Therapeutics Inc's reporting currency: US Dollar USD
47.12%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 31 Mar 2025 | 6.05m | 9.47% |
| Janus Henderson Investors US LLCas of 31 Mar 2025 | 5.57m | 8.73% |
| Opaleye Management, Inc.as of 09 Apr 2025 | 3.95m | 6.19% |
| Millennium Management LLCas of 12 Jun 2025 | 3.56m | 5.59% |
| BlackRock Fund Advisorsas of 31 Mar 2025 | 2.84m | 4.45% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Mar 2025 | 2.60m | 4.07% |
| The Vanguard Group, Inc.as of 31 Mar 2025 | 2.17m | 3.40% |
| Alyeska Investment Group LPas of 31 Mar 2025 | 1.44m | 2.26% |
| Renaissance Technologies LLCas of 31 Mar 2025 | 974.97k | 1.53% |
| Geode Capital Management LLCas of 31 Mar 2025 | 907.96k | 1.42% |
More ▼
Data from 31 Mar 2025 - 31 Mar 2025Source: FactSet Research Systems Inc.
